查看2014.Doxorubicin.HSA的源代码

=== 患者群体 (Patient population) ===
评估了 8 年（2005-2013 年）在单个兽医转诊中心（红岸兽医医院）就诊的推定心脏 HSA 的狗的医疗记录，以确定符合条件的患者。纳入本研究的标准如下：根据位置（右心房、右耳廓、房室沟、房室或三尖瓣、无心室壁）和/或异质性或空腔超声外观，强烈怀疑为 HSA 的原发性心脏肿瘤;至少进行一次完整的超声心动图检查;以及充分的随访信息，以便进行结果分析。排除显示回声特征或更提示化疗瘤或其他非血管性心脏肿瘤的解剖位置的肿瘤。如果狗因心脏肿瘤而接受手术干预（切除或心包切除术），则不包括在内。诊断时有转移的影像学或超声学证据的患者符合纳入条件。根据业主的意愿决定使用DOX进行全身治疗;然而，所有纳入的患者都接受了肿瘤科医生的会诊。

Medical records of dogs presenting for presumed cardiac HSA at a single veterinary referral centre (Red Bank Veterinary Hospital) over an 8-year period (2005–2013) were evaluated to identify eligible patients. Criteria for inclusion in this study were as follows: a primary cardiac tumour strongly suspected to be HSA based on the location (right atrium, right auricle, AV groove, AV or tricuspid valve, ventricular-free wall) and/or heterogeneous or cavitated ultrasonographic appearance; at least one full echocardiogram performed; and adequate follow-up information to allow for outcome analysis. Tumours displaying echogenic characteristics or an anatomic location more suggestive of a chemodectoma or other non-vascular cardiac tumour were excluded. Dogs were not included if they underwent surgical intervention (either resection or pericardiectomy) for their cardiac tumour. Patients with radiographic or ultrasonographic evidence of metastasis at diagnosis were eligible for inclusion. The decision to pursue systemic treatment with DOX was made according to owner preference; however, all included patients underwent consultation with an oncologist.

从病历中获得的信息包括品种;年龄;性;重量;初次就诊和诊断的日期;提出投诉;分期试验的结果;超声心动图结果包括肿瘤大小、是否存在心包填塞、进行的心包穿刺次数、是否进行治疗、化疗方案、治疗反应、治疗相关不良事件 （AE）、死亡日期和尸检结果（如果进行）。病历中没有的随访信息是通过与主人和/或转诊兽医的电话联系获得的。使用上述方法跟踪所有狗，直到死亡或失去联系。

Information obtained from the medical records included breed; age; sex; weight; date of initial presentation and diagnosis; presenting complaint; results of staging tests; echocardiogram findings including size of tumour, the presence of tamponade, the number of pericardiocenteses performed, whether treatment was pursued, chemotherapy protocol, treatment response, treatment-related adverse events (AEs), date of death and necropsy results if performed. Follow-up information not available in the medical record was obtained over telephone contact with owners and/or referring veterinarians. All dogs were followed until the time of death or loss of contact using the above methods.

<br>